Delving into the Latest Updates on Meilaipu (Beijing) Pharmaceutical Research Co., Ltd. with Synapse

Overview

Tags

Otorhinolaryngologic Diseases

Congenital Disorders

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

CSF-1R x FGFRs x FLT3 x PDGFR x VEGFR	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Nintedanib esylate ( CSF-1R x FGFRs x FLT3 x PDGFR x VEGFR )	Advanced Lung Non-Small Cell Carcinoma More	Phase 3
Salmeterol xinafoate/Tiotropium Bromide Hydrate ( M3 receptor x β2-adrenergic receptor )	Pulmonary Disease, Chronic Obstructive More	Discontinued